Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Better4All Personalized Intervention Pilot Study

NCT07120802 · tracked via the Priya Life Science Sweden tracker
Phase
Not applicable
Started
2025-06-01
Last updated
2025-08-13

Condition(s) studied

Obesity Prevention

Investigational drug(s) / intervention(s)

BETTER4U Mobile App and Wearable Use (End-User Group)BETTER4U Intervention Platform Testing (Implementer Group)

BETTER4U Mobile App and Wearable Use (End-User Group): Participants from the general population ("end-users") will use a smartwatch and the BETTER4U mobile app for 21 days. The app passively collects data (physical activity, sleep, eating behaviors, environment), while participants may self-report certain behaviors. The goal is to assess the usability, feasibility, and acceptability of the tools and to collect real-world behavioral data for refining AI models.

BETTER4U Intervention Platform Testing (Implementer Group): Healthcare professionals and other potential implementers will test the BETTER4U Intervention Platform and mobile app for 7 days. They will assess system usability, complete synthetic case simulations, and provide daily feedback via Google Forms. They also wear the smartwatch and use the app for data validation purposes. The goal is to evaluate platform usability and collect ground-truth data for validating AI algorithm outputs.

Study summary

The BETTER4U project (Preventing obesity through Biologically and bEhaviorally Tailored inTERventions for you) is funded by the European Union (EU) and involves an international consortium consisting of 28 partners across Europe, Israel, and Australia. The project started in November 2023 and will run until October 2027. The main aim of BETTER4U is to improve weight management through a tailor-made intervention, the "BETTER4ALL personalized intervention", using modern monitoring tools and artificial intelligence (AI), including machine learning (ML) practices.

In the context of the BETTER4U project, the present Pilot Study aims to a) evaluate the usability, feasibility and acceptability of the BETTER4U mobile application ("BETTER4U App") and Intervention Platform that will be used to monitor and collect data from participants in the BETTER4ALL personalized intervention (randomized controlled trial; RCT) and b) collect data to evaluate and improve the BETTER4U causal AI models for the prevention of weight gain, before deploying them at large scale, as well as test and identify the optimal ways of delivering the AI-based interventions to the participants. The study will be conducted in seven sites in Cyprus, France, Greece, Poland, Portugal, Spain, and Sweden.

The BETTER4All Pilot Study will be a longitudinal, correlational, observational study, including a total of n=490 participants, equally distributed among the seven sites (i.e. n=70 per site). Specifically, n=60 (± 3-5) "general population" participants (henceforth: "end-users" of the wearables and the BETTER4U App) and n=10 (± 3-5) healthcare or other types of providers (henceforth: potential "implementers" of the BETTER4U intervention) will constitute each site's sample.

The study will involve the following two components: a) the administration of the wearables (smartwatches) to the "end-users" and their registration to and training on the BETTER4U App, to be used for a total duration of three weeks (21 days). During this period, their lifestyle behaviours (i.e. "BETTER4U Core Behavioural Indicators - BCBIs", such as eating occasions, physical activity, sedentary time, sleep etc.) and "living environment indicators - LEIs"; (e.g. access to parks in your area, distance from your home to your work place etc.) will be recorded daily, either in an automated way via the wearables or self-reported by the end-users through the App; and b) the registration to and training on the BETTER4U Intervention Platform of the "implementers" for a total duration of one week (7 days), during which they will be asked to test the platform's functionalities using synthetic data. The implementers will also be provided with the wearables and the App (similarly to the end-users) for one week only to allow collection of additional data that will help verify the accuracy of the algorithms in the gathered data from the wearables/monitoring tools regarding BCBIs and LEIs.

Overall, the outcomes and the findings of the Pilot Study will be used to further refine, optimize, and adjust the tools for the BETTER4ALL RCT, according to the feedback received by both end-users' and implementers' perspectives.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Age: Participants aged 18-65 years to represent the adult general population. * Body Mass Index (BMI): * Overweight or obesity group: BMI ≥ 25 kg/m². * Normal weight group: BMI 18.5-24.9 kg/m². * Technology Use: * Willingness and ability to use wearable devices and an Android mobile application for the duration of the study. * Owning a smartphone device with the Android operating system. * Eating utensil technique: dominant hand gestures that correspond to handling of food via a fork or a spoon. * Language Proficiency: Ability to read and understand the language in which the mobile app and study materials are provided. * Consent: Willing to provide informed consent to participate in the study. * Residency: Must be a resident of one of the seven participating countries. * Availability: Able to participate for the full three-week duration of the study and comply with the study protocol. Exclusion Criteria: * Health Conditions: Pregnant or breastfeeding women, as they might have different lifestyle behaviours or health needs. * Physical Limitations: Any physical or mental condition that would prevent the participant from using the wearable device or mobile application as intended. * Eating utensil technique: eating food with chopsticks on a daily or regular basis. * Technical Incompatibility: Individuals who do not own a compatible smartphone or are unable to use the provided wearable devices for technical reasons.

Primary outcome measure(s)

  • System Usability Scale (SUS) Score - End-Users — Day 21 (end of participation period for end-users)
    Usability of the BETTER4U App as reported by end-users using the validated SUS questionnaire (10 items, total score 0-100).
  • System Usability Scale (SUS) Score - Implementers — Day 7 (end of participation period for implementers
    Usability of the BETTER4U App and Intervention Platform as reported by implementers using the validated SUS questionnaire. Unit of Measure: Mean SUS score (0-100).
  • Acceptability of Intervention Measure (AIM) Score - End-Users — Day 21
    Acceptability of the BETTER4U App rated by end-users using the AIM (4 items, 5-point Likert scale). Unit of Measure: Mean AIM score (1-5)
  • AIM Score - Implementers — Day 7
    Acceptability of the BETTER4U Intervention Platform rated by implementers using AIM. Mean AIM score (1-5)
  • Feasibility of Intervention Measure (FIM) Score - End-Users — Day 21
    Feasibility of the BETTER4U App as perceived by end-users. Mean FIM score (1-5)
  • FIM Score - Implementers — Day 7
    Feasibility of the BETTER4U Intervention Platform as perceived by implementers. Mean FIM score (1-5).
  • Intervention Appropriateness Measure (IAM) Score - End-Users — Day 21
    Appropriateness of the BETTER4U App as rated by end-users. Mean IAM score (1-5).
  • IAM Score - Implementers — Day 7
    Appropriateness of the BETTER4U Intervention Platform as rated by implementers.Mean IAM score (1-5)

Trial sites (7)

FacilityCityRegionStatus
University of Cyprus (Ucy) Nicosia Cyprus Recruiting
Universite Lyon 1 Claude Bernard (Ucbl) Villeurbanne France Recruiting
Harokopio University Athens Aticca Recruiting
Uniwersytet Swps (Swps) Wroclaw Poland Recruiting
Centro de Estudos E Investigacao Em Dinamicas Sociais E Saude Associacao Sem Fins Lucrativos (Ceidss) Lisbon Portugal Recruiting
Universidad de Navarra (Unav) Pamplona Navarre Recruiting
Karolinska Institutet Huddinge Sweden Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07120802 on ClinicalTrials.gov ↗ ← All trials in Sweden